BioVie Strengthens Board with Two New Appointments

Author: Addison Perry Updated: 07-22-2025 08:21 AM

BioVie Welcomes New Members to Board of Directors

BioVie Inc. (NASDAQ: BIVI), a pioneering clinical-stage company, announces the strategic appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors. This decision comes as the company continues to innovate in the treatment of neurological and neurodegenerative disorders, including early Parkinson's disease and long COVID.

Expertise and Vision for Change

Cuong Do, President and CEO of BioVie, emphasized the significance of these appointments. Both Amy and Kameel are esteemed individuals whose backgrounds in drug development and commercialization bring a wealth of knowledge to BioVie. Their collective experience is crucial as the company accelerates its efforts in clinical development, particularly with its promising candidate, bezisterim.

Amy S. Chappell: A Wealth of Experience

Dr. Chappell's extensive experience in clinical neuroscience spans over two decades. During her impressive tenure at Eli Lilly & Co., she was instrumental in the development and FDA approvals of vital therapies, significantly impacting patients suffering from chronic conditions. As the Chief Medical Officer at Solaxa Inc., her strategic insights continue to shape the development of innovative therapies.

Kameel D. Farag: A Proven Track Record

With a robust background in global finance, Mr. Farag previously served as Chief Financial Officer at Aspen Neuroscience, where he facilitated significant growth and capital acquisition. His financial acumen will prove invaluable as BioVie embarks on the next chapter of its clinical development journey.

Current Clinical Developments and Future Plans

BioVie is currently advancing its Phase 2 trials for bezisterim while preparing further clinical studies for Alzheimer's disease and ascites. The recent data presented at renowned conferences highlights bezisterim's potential in addressing neurodegeneration, making BioVie a company to watch in the biopharmaceutical domain.

Upcoming Clinical Trials

The launch of the ADDRESS-LC trial focused on long COVID marks another milestone for BioVie. This initiative exemplifies the company's commitment to patient-centered clinical innovation. Their ongoing SUNRISE-PD study represents vital steps in Parkinson's disease research.

About BioVie Inc.

BioVie is dedicated to creating transformative therapies specifically targeting neurological disorders and advanced liver disease. Their drug candidate, bezisterim, operates by modulating inflammatory responses that contribute to conditions like Alzheimer’s and Parkinson’s disease. Furthermore, BioVie’s orphan drug candidate BIV201 is under FDA Fast Track designation, signaling a promising future in liver disease treatment.

Frequently Asked Questions

What recent appointments have been made to BioVie’s Board?

Amy S. Chappell and Kameel D. Farag have joined the Board of Directors of BioVie Inc.

What is BioVie’s primary focus?

BioVie focuses on developing innovative therapies for neurological disorders and advanced liver diseases.

What is bezisterim?

Bezisterim is BioVie’s drug candidate aimed at mitigating neuroinflammation and helping in conditions related to Alzheimer’s and Parkinson’s diseases.

What trials is BioVie currently conducting?

BioVie is conducting Phase 2 trials for bezisterim and trials for long COVID and Parkinson’s disease.

Where can I find more information about BioVie?

For additional details, you can visit BioVie’s official website.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.